153 related articles for article (PubMed ID: 24576172)
1. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry.
Crawford ED; Scholz MC; Kar AJ; Fegan JE; Haregewoin A; Kaldate RR; Brawer MK
Curr Med Res Opin; 2014 Jun; 30(6):1025-31. PubMed ID: 24576172
[TBL] [Abstract][Full Text] [Related]
2. Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2017; 17(6):1-75. PubMed ID: 28572867
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer.
Shore N; Concepcion R; Saltzstein D; Lucia MS; van Breda A; Welbourn W; Lewine N; Gustavsen G; Pothier K; Brawer MK
Curr Med Res Opin; 2014 Apr; 30(4):547-53. PubMed ID: 24320750
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer.
Shore ND; Kella N; Moran B; Boczko J; Bianco FJ; Crawford ED; Davis T; Roundy KM; Rushton K; Grier C; Kaldate R; Brawer MK; Gonzalgo ML
J Urol; 2016 Mar; 195(3):612-8. PubMed ID: 26403586
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
Sommariva S; Tarricone R; Lazzeri M; Ricciardi W; Montorsi F
Eur Urol; 2016 Jan; 69(1):107-15. PubMed ID: 25481455
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.
Canter DJ; Freedland S; Rajamani S; Latsis M; Variano M; Halat S; Tward J; Cohen T; Stone S; Schlomm T; Bishoff J; Bardot S
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):102-107. PubMed ID: 31243337
[TBL] [Abstract][Full Text] [Related]
9. Cell-cycle Progression-score Might Improve the Current Risk Assessment in Newly Diagnosed Prostate Cancer Patients.
Oderda M; Cozzi G; Daniele L; Sapino A; Munegato S; Renne G; De Cobelli O; Gontero P
Urology; 2017 Apr; 102():73-78. PubMed ID: 27894974
[TBL] [Abstract][Full Text] [Related]
10. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
[TBL] [Abstract][Full Text] [Related]
11. Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study.
Michalopoulos SN; Kella N; Payne R; Yohannes P; Singh A; Hettinger C; Yousefi K; Hornberger J;
Curr Med Res Opin; 2014 Aug; 30(8):1547-56. PubMed ID: 24803160
[TBL] [Abstract][Full Text] [Related]
12. Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.
Koch MO; Cho JS; Kaimakliotis HZ; Cheng L; Sangale Z; Brawer M; Welbourn W; Reid J; Stone S
Cancer Biomark; 2016 Jun; 17(1):83-8. PubMed ID: 27314296
[TBL] [Abstract][Full Text] [Related]
13. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
14. Specimen Provenance Testing Identifies Contamination That Affects Molecular Prognostic Assay Results in Prostate Cancer Biopsy Specimens.
Wojno L; Minutella C; Moylan D; Bush A; Wojno K
Urology; 2018 May; 115():87-91. PubMed ID: 29476774
[TBL] [Abstract][Full Text] [Related]
15. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.
Mortensen MB
Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296
[TBL] [Abstract][Full Text] [Related]
16. A novel technique using three-dimensionally documented biopsy mapping allows precise re-visiting of prostate cancer foci with serial surveillance of cell cycle progression gene panel.
Ukimura O; Gross ME; de Castro Abreu AL; Azhar RA; Matsugasumi T; Ushijima S; Kanazawa M; Aron M; Gill IS
Prostate; 2015 Jun; 75(8):863-71. PubMed ID: 25663102
[TBL] [Abstract][Full Text] [Related]
17. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
18. Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists' recommendations for active treatment or active surveillance: a randomized clinical utility trial.
Peabody JW; DeMaria LM; Tamondong-Lachica D; Florentino J; Czarina Acelajado M; Ouenes O; Richie JP; Burgon T
BMC Urol; 2017 Jul; 17(1):51. PubMed ID: 28673277
[TBL] [Abstract][Full Text] [Related]
19. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
[TBL] [Abstract][Full Text] [Related]
20. Compliance with biopsy recommendations of a prostate cancer risk calculator.
van Vugt HA; Roobol MJ; Busstra M; Kil P; Oomens EH; de Jong IJ; Bangma CH; Steyerberg EW; Korfage I
BJU Int; 2012 May; 109(10):1480-8. PubMed ID: 21933335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
